Skip to main content
. 2023 Aug 17;10:1215927. doi: 10.3389/fmed.2023.1215927

Figure 2.

Figure 2

Sample size calculations for select human studies using G*Power. (A) Sample size calculations based on expected proportions of response for rifaximin vs. placebo in irritable bowel syndrome with type I error of 0.05 and power of 0.95. (B) Sample size calculations based on the expected incidence of postoperative acute kidney injury with dexmedetomidine infusion vs. placebo with type I error of 0.05 and power of 0.8.